Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
40 participants
INTERVENTIONAL
2024-10-16
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Training Dose on Computerized Cognitive Training in Patients With Cognitive Impairment
NCT05922319
Non-pharmacological Interventions on Cognitive Functions in Older People With Mild Cognitive Impairment
NCT03545152
Effect of High Altitude Exposure, Acclimatization and Re-exposure on Sustained Attention in Lowlanders
NCT02738307
MIND Diet and Cognitive Function in Adults With MCI
NCT05975723
Evaluation of the Effect of Healthy Lifestyle Intervention for Patients With Mild Cognitive Impairment
NCT06942780
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
PREVENTION
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low temperature (15℃) group
Subjects in the exposure group will be exposed to low temperature (15℃) for about 2 hours in a chamber.
Low temperature (15℃) group
The exposure group will be exposed to low temperature (15℃) in a chamber for about 2 hours, resting during the whole period.
Moderate temperature (22℃) group
Subjects in the exposure group will be exposed to moderate temperature (22℃) for about 2 hours in a chamber.
Moderate temperature (22℃) group
The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low temperature (15℃) group
The exposure group will be exposed to low temperature (15℃) in a chamber for about 2 hours, resting during the whole period.
Moderate temperature (22℃) group
The exposure group will be exposed to thermoneutral temperature (22℃) in a chamber for about 2 hours, resting during the whole period.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index \> 18.5 and ≤ 28;
* right-handed;
* receiving or having received higher education;
* with the ability to read and understand Chinese smoothly.
Exclusion Criteria
* Current drug and dietary supplements intake;
* Subjects with allergic diseases, such as allergic rhinitis, allergic asthma, and atopy;
* Subjects with cardiovascular diseases, such as congenital heart disease, pulmonary heart disease, and hypertension;
* Subjects with respiratory diseases, such as asthma, chronic bronchitis, and chronic obstructive pulmonary disease;
* Subjects with chronic diseases, such as diabetes, chronic hepatitis, and kidney disease;
* Subjects who have a history of major surgery due to the cardiovascular, cerebrovascular, respiratory, or neurological diseases;
* Subjects with neurologic disorders, such as stroke, traumatic brain injury, epilepsy, and schizophrenia;
* Abnormal spirometry (FEV1 and FVC ≤ 75% of predicted and FEV1/FVC ≤ 0.65);
* Subjects with color vision disabilities.
18 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fudan University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Renjie Chen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Haidong Kan, PhD
Role: STUDY_DIRECTOR
Fudan University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Environmental Health, School of Public Health, Fudan University
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB#2024-10-1168
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.